Lead Bioinformatics Developer

Lead Bioinformatics Developer

The Lead Bioinformatics Developer will own and drive the development and continuous improvement of proprietary, scalable bioinformatics tools for multi‑omic data analysis in support of MaaT Pharma’s discovery and translational platforms.

He/She will combine expertise in software engineering practices with domain expertise in multi‑omic analysis, oversee industrialization, cloud deployment, and scaling of solutions in a highly secure environment, perform GxP validations when required, and ensure compliance with quality and regulatory standards.

He/She will provide expert support to operational teams and guarantee the performance and security of the tools and hosting computing infrastructure.

Company

MaaT Pharma (Microbiota as a Therapy) is a clinical‑stage biotechnology company focused on restoring patient‑microbiome symbiosis in oncology and graft‑versus‑host disease (GvHD). The company launched a Phase 3 clinical trial in March 2022 for acute GvHD patients, following a successful Phase 2 trial. Its discovery and analysis platform, gutPrint®, supports pipeline development by determining disease targets, evaluating drug candidates, and identifying biomarkers for microbiome‑related conditions.

The company’s microbiome ecosystem therapies are produced via a standardized cGMP manufacturing and quality control process, delivered in liquid and oral formulations. MaaT Pharma has gained support from regulators and was listed on Euronext Paris in November 2021 (Ticker: MAAT).